In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens |
| |
| Authors: | Lawrence Laura Danese Paul DeVito Joe Franceschi Francois Sutcliffe Joyce |
| |
| Affiliation: | Rib-X Pharmaceuticals, Inc., 300 George Street, New Haven, Connecticut 06511, USA. |
| |
| Abstract: | Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
